CancerFax
Cancer Knowledge Hub β€” Expert-reviewed insights

Cancer insights that inform better decisions

Step-by-step guides, research summaries, and treatment overviews β€” reviewed by oncology navigators and written clearly for patients, families, and caregivers.

From newly diagnosed to relapsed and refractory β€” we publish what patients actually need to understand their options.

Reviewed by oncology navigators Updated regularly 50+ countries reached Clinically grounded
What you'll find here

Insights built for complex decisions

CancerFax Insights exists because cancer patients face decisions that are genuinely hard β€” not because of lack of will, but because the information landscape is fragmented, fast-moving, and often written for clinicians, not families.

Every insight published here is reviewed by our oncology navigation team before it goes live. We focus on the questions patients actually ask us: What is this treatment? Who qualifies? What should I prepare? What should I ask my doctor?

Use the search and filters below to find what's most relevant to your situation.

Cancer insights library

Browse the full library

Search, filter, and explore all published insights β€” by cancer type, treatment category, clinical trial readiness, or stage of your journey.

Search across cancer types, treatments, mutations, drugs, and trials

Topic

9 of 121 insights

Insight

Insight

GPRC5D CAR-T for Multiple Myeloma β€” What Patients Need to Know

Insight

Insight

Immune Reconstitution After CAR-T: What to Expect

Insight

Insight

Allogeneic (Off-the-Shelf) CAR-T: The Next Frontier

Insight

Insight

CAR-T Cell Therapy for Autoimmune Disorders

Insight

Insight

CAR-T for Multiple Myeloma in China β€” BCMA-Directed Therapies

Insight

Insight

CD19/CD22 Bispecific CAR-T: What Patients Need to Know

Insight

Insight

Equecabtagene Autoleucel (CT053): China's Domestically Approved Myeloma CAR-T

Insight

Insight

Extramedullary Myeloma: Challenges and CAR-T Considerations

CAR-T

CAR-T

CAR-T Costs in China vs USA and Europe: The Complete Cost Comparison

CAR-T therapy in China costs $100,000–180,000 all-in for the full treatment episode, compared to $500,000–700,000 in the USA and comparable figures in Europe. Approved Chinese CAR-T products including relma-cel and BCMA-targeted therapies offer equivalent efficacy at a fraction of Western drug prices. CancerFax navigates cost, hospital selection, and access logistics for international patients.

By cancer type

Insights by cancer type

Find content specific to your diagnosis β€” from treatment overviews to clinical trial access and second opinion guidance.

Clinical trial access

Access to trials unavailable at home

CancerFax connects patients with clinical trials in China, India, and leading global centres β€” including phase I and II trials closed to international enrolment through standard channels.

500+

active clinical trials across China, India, and leading global centres

40+

cancer types with current advanced therapy access pathways

12+

years of patient navigation experience in cross-border oncology

A note from the CancerFax team

Why we publish independently

CancerFax Insights is editorially independent of the hospitals, pharmaceutical companies, and treatment centres we work with. Our navigation team writes what patients need to hear β€” not what any institution wants them to read.

That means we tell patients when a treatment is likely out of reach, when a clinical trial has closed, and when the evidence for a new therapy is still thin. We believe informed patients make better decisions and have better outcomes β€” even when the honest answer is harder to hear.

β€” CancerFax oncology navigation team

Questions

About CancerFax Insights

How our content is produced, reviewed, and how to use it effectively.

What kind of insights does CancerFax publish?
CancerFax publishes expert-reviewed, patient-facing content covering advanced cancer treatments, clinical trials, precision oncology, international care pathways, and caregiver guidance. Every insight is reviewed by our oncology navigation team before publication.
Are these insights written for patients or medical professionals?
Our insights are written primarily for patients, families, and caregivers β€” but are clinically grounded enough to be a useful reference for healthcare professionals. We aim for clarity without oversimplification.
How often is content updated?
Insights are reviewed and updated regularly, especially when new clinical data or trial results change the standard of care. The last review date is shown on each article.
Can I use these insights to make treatment decisions?
Our insights are educational β€” they help you understand options, ask better questions, and prepare for medical consultations. They do not replace the advice of your treating oncologist. If you need structured guidance for your specific case, our navigation team can help.
How do I find insights relevant to my cancer type?
Use the search bar above to filter by cancer type, treatment name, mutation, or stage. You can also browse by topic category using the filter pills, or use the cancer type tags in the sidebar.
Ready to go further?

Get personalised guidance for your case

Our oncology navigators review your medical records, explain your options in plain language, and help you access the right specialists, trials, and treatment centres β€” wherever you are in the world.

Every navigation request is reviewed by a qualified oncology professional. We do not recommend treatments without reviewing your medical records.